<DOC>
	<DOCNO>NCT01235949</DOCNO>
	<brief_summary>The aim current study determine whether ibuprofen , give immediate delay prophylactic antipyretic treatment standardized manner , significantly impact immune response child receive primary vaccination GlaxoSmithKline ( GSK ) Biologicals ' 10-valent pneumococcal conjugate vaccine , co-administered DTPa-combined vaccine , 3 , 4 5 month age . In addition , study evaluate impact prophylactic administration paracetamol follow primary vaccination immediate delay administration give immediate manner time booster dose .</brief_summary>
	<brief_title>Primary Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A Prophylactic Antipyretic Treatment</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Antipyretics</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol . A male female , include , 12 16 week ( 84118 day ) age time first vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject . Free obvious health problem establish medical history clinical examination enter study . Born gestation period 36 42 week inclusive . Use investigational nonregistered product study vaccines/products within 30 day precede first dose study vaccine/product , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( . Indication , specify protocol , prophylactic therapeutic antipyretic treatment study period . Treatment antipyretics 24 hour study vaccination plan administration antipyretic 24 hour study vaccination . Chronic administration immunosuppressant immunemodifying drug since birth . Planned administration/administration vaccine foreseen study protocol period start 30 day dose study vaccine end 30 day exception locally recommend ( pandemic ) influenza vaccine , document eCRF . Previous vaccination diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b and/or Streptococcus pneumoniae exception vaccine first dose may give within first two week life accord national recommendation . History intercurrent diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b disease . History allergic disease reaction likely exacerbate component vaccine prophylactic antipyretic treatment , i.e . ibuprofen paracetamol , specify protocol . History seizures progressive neurological disease . Acute disease and/or fever time enrolment . The study entry delay illness improve . Any confirmed suspected immunosuppressive immunodeficient condition , base medical history physical examination . A family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . Administration immunoglobulins and/or blood product since birth plan administration entire study period . Any contraindication treatment ibuprofen describe ibuprofen summary product characteristic ( SPC ) . Any contraindication treatment paracetamol describe paracetamol SPC . Body weight &lt; 5 kg time enrolment . Child care .</criteria>
	<gender>All</gender>
	<minimum_age>12 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Fever</keyword>
	<keyword>Primary vaccination</keyword>
	<keyword>Booster vaccination</keyword>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Prophylactic antipyretic</keyword>
</DOC>